Evidence map›Paper›PMID 35769787›Full record

ArticleFrontiers in public health2022

Real-World Impact of Switching From Insulin Glargine (Lantus

Yazed AlRuthia, Ohud H Bahari, Suliman Alghnam, Ali M Alrumaih, Hassan Asiri, Mohammed Alshammari, Mansour Alhowimel, Hana A Al-Abdulkarim

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Yazed AlRuthiaDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Ohud H BahariDepartment of Pharmaceutical Care, King Saud Medical City, Riyadh, Saudi Arabia.
Suliman AlghnamKing Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.
Ali M AlrumaihPharmaceutical Care Department, Medical Services for Armed Forces, Ministry of Defense, Riyadh, Saudi Arabia.
Hassan AsiriDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Mohammed AlshammariDrug Policy and Economic Center, National Guard Health Affairs, Riyadh, Saudi Arabia.
Mansour AlhowimelNational Unified Procurement Company (NUPCO), Riyadh, Saudi Arabia.
Hana A Al-AbdulkarimKing Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.
King Saud University · SAKing Abdulaziz Medical City · SAKing Abdullah International Medical Research Center · SAKing Saud Medical City · SANational Guard Health Affairs · SARiyadh Armed Forces Hospital · SASaudi Heart Association · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The advent of Basaglar Methods: This was a single-center retrospective chart review study of adult patients (e.g., ≥18 years) with diabetes mellitus (DM) who were treated with insulin glargine (Lantus Results: One-hundred patients with DM who were previously treated with Lantus Conclusion: Basaglar

Indexed as

Biosimilar PharmaceuticalsAdultCost SavingsDelivery of Health CareFemaleGlycated HemoglobinHumansHypoglycemic AgentsInsulin GlargineMaleRetrospective StudiesSaudi ArabiaBiosimilar PharmaceuticalsGlycated HemoglobinHypoglycemic AgentsInsulin GlargineBasaglar®cost savingsdiabetes mellitusinsulin glargineLantus®Saudi Arabia

Identifiers

PMID35769787
PMCPMC9234164
OpenAlexW4282568485

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.